Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms

Last updated: March 19, 2018
Sponsor: Timothy Boone, MD, PhD
Overall Status: Completed

Phase

4

Condition

Interstitial Cystitis

Enuresis

Treatment

N/A

Clinical Study ID

NCT01457573
Pro00006253
IRB# 0711-0124
  • Ages > 45
  • Male

Study Summary

A single center, pilot trial using tamsulosin and solifenacin in 10 men with symptomatic lower urinary tract symptoms (LUTS). Subjects will be evaluated at baseline, 1, 2, and 3 months for urinary NGF, urine creatinine, NGF/CR ratio and patient reported outcomes through questionnaires.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men > 45 years old with symptomatic LUTS (clinical benign prostatic hypertrophy/BPH)

  • International Prostate Symptom Score (IPSS) > 8

  • PSA < 10 ng/ml (negative biopsies within 6 months for any age-specific PSA elevationsuspicious for prostate carcinoma)

  • Post void residual urine < 150 mls

  • Urinary Flow rate > 15 mL/sec

Exclusion

Exclusion Criteria:

  • Neurogenic bladder

  • Urinary tract infection, Urinary stone(s), Urinary tract tumor

  • Radiation therapy for urologic malignancy or prostate surgery; radiation to pelvic,colon, rectum, prostate, bladder, uterus or ovaries

  • Alpha blocker therapy or anticholinergic therapy within 3 months of entry or 5 alphareductase therapy within 18 months.

  • History of cataracts with planned surgery

Study Design

Total Participants: 10
Study Start date:
October 01, 2011
Estimated Completion Date:
July 31, 2014

Study Description

Single center, pilot trial, single arm study using once daily dosing of tamsulosin and solifenacin in 10 men with symptomatic lower urinary tract symptoms (LUTS). Assessments occur at Baseline, 1 Month, 2 Month and 3 Month to evaluate: urinary NGF (pg/mL), urine creatinine (mg/dL), NGF/Cr ratio and patient reported questionnaire outcomes (AUA Symptom Score/IPSS, Patient Perception of Bladder Condition, Patient Perception of Urge Intensity 'PPIUS', LUTS Urinary Symptoms and Quality of Life). Each participant is assessed from baseline to Month 3 measurements. Protection of human subjects will be provided through the Houston Methodist Research Institute Institutional Review Board (see appendix 2). All men will receive morning dosing with Tamsulosin 0.4 mg (1 tab) and Solifenacin 5 mg (1 tab) orally at the same time.

Connect with a study center

  • The Methodist Hospital System

    Houston, Texas 77030
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.